BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.
Email Alerts
Email Alerts
Recent BDSI News
BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting
January 15, 2021
Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C. , Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty ...
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference
November 20, 2020
RALEIGH, N.C. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey , Chief Executive Officer, and ...
BioDelivery Sciences to Present Virtually and Host 1x1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18
November 11, 2020
RALEIGH, N.C. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Chief Executive Officer, and ...